MedTrace Logo

Effectiveness of Mucolox® and Clonazepam in Treatment of Burning Mouth Syndrome

NCT02690844 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2018-05-03

No results posted yet for this study

Summary

What affect does the use of a mucoadhesive drug delivery system (Mucolox®) compounded with clonazepam have in the treatment of burning mouth syndrome?

There are no clinical trials reported in the literature that evaluate the use of a mucoadhesive vehicle to deliver clonazepam into the oral cavity and treat burning mouth syndrome. The use of a mucoadhesive may help to increase surface contact and elicit a greater reduction in symptoms.

Conditions

  • Burning Mouth Syndrome

Interventions

DRUG

Clonazepam mixed with Mucolox®

1mg clonazepam in 5mL Mucolox® will be used TID. Mixture will be swished around mouth for 3 minutes then spat out.

DRUG

Mucolox® alone

5mL Mucolox® TID. Mixture swished around mouth for 3 minutes then spat out.

DRUG

Clonazepam

1mg Clonazepam tablet will be used TID. Tablet dissolved in mouth, swished around and then expectorated.

Sponsors & Collaborators

  • University of Alberta

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2016-05-31
Completion
2016-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02690844 on ClinicalTrials.gov